ArticleInternational medical case reports journal2024
Bilateral Reversible Corneal Edema as a Novel Side-Effect of Levetiracetam - A Case Report.
Article in International medical case reports journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: We present a case of levetiracetam-induced corneal edema. To the best of our knowledge, this is the first documented case of bilateral reversible corneal edema secondary to levetiracetam use. Patients and Methods: A 59-year-old woman was referred to the ophthalmology department with a few weeks' history of bilateral blurring of vision. She is a known case of secondary progressive multiple sclerosis, and she was started on levetiracetam by her neurologist a few weeks prior to referral in view of new seizure activity. Examination revealed bilateral clinically evident corneal edema, which was documented on corneal topography. Results: Upon levetiracetam dose reduction, symptoms started to improve and eventually the medication was stopped altogether. The patient's vision and corneal edema normalized on follow-up. Conclusion: This novel side effect should be kept in mind when a patient who is on levetiracetam presents with corneal edema as this can avoid misdiagnosis and unnecessary interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.